Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease that affects the filtration system of the kidney (glomeruli) and causes severe scarring and end-stage renal failure. According to an article published in the Clinical Journal of the American Society of Nephrology in 2017, the incidence of FSGS is 1.5 times higher in males than in women. Edema, proteinuria, weight gain, elevated cholesterol, and proteins in the blood are all indications of FSGS.
Market Drivers for Focal Segmental Glomerulosclerosis
There is currently no approved medicine for the treatment of FSGS. As a result, the Focal Segmental Glomerulosclerosis Market is predicted to develop due to restricted treatment options and government financing for rare illness research. For example, the US Food and Medication Administration (FDA) and the European Commission both designated Sparsentan as an orphan drug for the treatment of FSGS in 2015. Spartan is a novel therapeutic candidate with a dual-mode of action that combines angiotensin receptor blockade and endothelin receptor blockade. It is currently being studied in a Phase III trial that is planned to finish in December 2022.
The Focal Segmental Glomerulosclerosis Market is also growing due to increased research & development by numerous producers for FSGS medications. Pfizer Inc., for example, is evaluating its medication PF-06730512 in people with primary focal segmental glomerulosclerosis in a clinical trial. This medication is now in Phase II testing, with results expected in June 2021.
Furthermore, government efforts in rare illness treatment are projected to propel the industry forward. According to a 2017 annual data report from the United States Renal Data System, Medicare spent roughly US$ 34 billion on dialysis patients with chronic renal disease.
Restraints in the Focal Segmental Glomerulosclerosis Market
The lack of public awareness about this disease and the high cost of dialysis therapy may limit the market's growth to some extent. According to a 2017 report published by the University of Michigan, knowledge among patients with FSGS is significantly low when they are in the early stages of the disease, which is impeding the FSGS market's growth.
Regional Analysis of the Focal Segmental Glomerulosclerosis Market
The global focal segmental glomerulosclerosis market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa, based on region.
Restraints in the Focal Segmental Glomerulosclerosis Market
The lack of public awareness about this disease and the high cost of dialysis therapy may limit the market's growth to some extent. According to a 2017 report published by the University of Michigan, knowledge among patients with FSGS is significantly low when they are in the early stages of the disease, which is impeding the FSGS market's growth.
Regional Analysis of the Focal Segmental Glomerulosclerosis Market
The global focal segmental glomerulosclerosis market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa, based on region.
0 Comments